Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 4 de 4
1.
Hum Exp Toxicol ; 41: 9603271211066066, 2022.
Article En | MEDLINE | ID: mdl-35137609

Background: Doxorubicin (Dox) is one of the most effective antineoplastic drugs which has severe cardiotoxic effects, limiting its clinical usage. Though the exact mechanism of doxorubicin-induced cardiotoxicity is yet to be elucidated, it is shown that production of reactive oxygen species (ROS) increases oxidative stress and leads to cardiomyocyte apoptosis and necroptosis which is also defined as a programmed cell death.Purpose: In the present study, we investigate the effects of necrostatin-1 (Nec-1)-an inhibitor of receptor interaction proteins 1 (RIP1) and necroptosis-on doxorubicin-induced cardiotoxicity in rats.Research Design: Hearts were isolated and perfused by the Langendorff system in all four groups. Perfusion pressure (PP), left ventricular developed pressure (LVDP) and heart rate per minute (HR), LV (dP/dt) max, and LV (dP/dt) min which shows cardiac contractility and relaxation were recorded.Results: Results showed that PP significantly increased with Dox treatment and significantly decreased with Nec-1 treatment, while HR, LVDP, LV (dP/dt) max, and LV (dP/dt) min values significantly decreased with the Dox-treated group and significantly increased with Nec-1 treatment. Also with Nec-1 treatment, gene expression levels of anti-apoptotic Bcl-2 significantly increased and pro-apoptotic protein Bax, apoptotic marker caspase-3, and Nox-2 significantly decreased compared to the Dox-treated group. In heart tissues, MDA levels were significantly increased with Dox and decreased with Nec-1 treatment. These results were supported by the histological analysis indicated that Nec-1 reduced doxorubicin-induced cellular injury.Conclusions: In conclusion, our data indicate that Nec-1 ameliorates doxorubicin-induced cardiotoxicity by reducing oxidative stress injury and attenuating apoptosis and necroptosis.


Cardiotoxicity/etiology , Cardiotoxicity/prevention & control , Doxorubicin/toxicity , Imidazoles/administration & dosage , Indoles/administration & dosage , Necroptosis/drug effects , Receptor-Interacting Protein Serine-Threonine Kinases/drug effects , Animals , Disease Models, Animal , Male , Protective Factors , Rats , Rats, Sprague-Dawley
2.
Arch Physiol Biochem ; 127(2): 148-152, 2021 Apr.
Article En | MEDLINE | ID: mdl-31172820

INTRODUCTION: There are few studies examining the effect of spinosad on cognitive functions in the literature. METHODS: In this study, we applied spinosad 3 weeks in different doses to mice and examined their effects on antioxidant system and cognitive performance. RESULTS: In the open field test, we observed a significant decrease (p < .05) in the total distance travelled and the time spent in the central area in all subjects who underwent spinosad. In the novel object recognition test, we observed decreases in the time spent with new and old objects. From the biochemical point of view, while BDNF and NGF levels were significantly lower in the spinosad applied group (p < .05), there was no difference in GPx and SOD levels (p > .05). CONCLUSIONS: These results show that spinosad disrupts cognitive functions at the doses we used in our study and this negative effect may be related to the decrease in neurotrophic factors.


Antioxidants/metabolism , Brain/drug effects , Cognition/drug effects , Insecticides/pharmacology , Macrolides/pharmacology , Oxidative Stress/drug effects , Animals , Brain/metabolism , Drug Combinations , Male , Mice , Mice, Inbred BALB C
3.
Biotechnol Biotechnol Equip ; 28(4): 674-680, 2014 Jul 04.
Article En | MEDLINE | ID: mdl-26019553

This study was performed to investigate the effect of ethyl pyruvate on changes in renal functions and oxidative stress related renal injury caused by cisplatin (cis-dichlorodiammine platinum-II; CDDP). Male Wistar albino rats were divided into four groups (n = 8): (1) control group (1 ml Ringer's lactate solution i.p.); (2) ethyl pyruvate (EP) group (50 mg/kg Ringer's EP solution (REPS) i.p.); (3) cisplatin group (a single dose of cisplatin (5 mg/kg, i.p.); and (4) cisplatin + EP group (a single dose of cisplatin (5 mg/kg, i.p.) + REPS 50 mg/kg/day, i.p.) for five days. At the sixth day, kidneys of rats were mounted to a Langendorff apparatus. Renal perfusion pressures were recorded. Blood samples were taken for serum urea, creatinine, total oxidant status (TOS), total antioxidant status (TAS) and oxidative stres index (OSI) evaluations. Kidney tissues were obtained for malondialdehyde (MDA) analyses and histopathological examination. Perfusion pressures, serum urea, creatinine, TOS, OSI and tissue MDA levels were found significantly higher, whereas TAS was notably lower in cisplatin group. Histopathological examination showed apparent renal paranchymal injury in cisplatin group. In cisplatin + REPS group, perfusion pressures, serum urea, creatinine and tissue MDA levels were decreased. Moreover, EP co-administration provided less inflammatory cell infiltration, tubular dilatation, whereas TOS, TAS and OSI improved significantly versus cisplatin group. These findings show that EP has protective effects against cisplatin nephrotoxicity.

4.
Clin Exp Pharmacol Physiol ; 29(8): 679-83, 2002 Aug.
Article En | MEDLINE | ID: mdl-12099999

1. In the present study, endothelium-derived relaxing factor (EDRF/nitric oxide (NO)), conversion of big endothelin (ET)-1 to endothelin-1 (ET-1) and the role of reactive oxygen species were investigated in kidneys isolated from glycerol (GLY)-pretreated rabbits. 2. Acetylcholine (ACh)-induced vasodilation that is due to the release of EDRF/NO is significantly decreased, whereas big ET-1-induced vasoconstriction was increased in kidneys isolated from GLY-pretreated rabbits. 3. Pretreatment of rabbits with the xanthine oxidase inhibitor allopurinol and the NO precursor L-arginine reversed the inhibition of ACh-induced vasodilation due to GLY and protects the kidney vasculature. 4. Big ET-1, but not ET-1, responses were found to be significantly increased in kidneys isolated from GLY-pretreated rabbits. This increase is attributed to the higher conversion rate of big ET-1 to ET-1 because the ET-converting enzyme (ECE) inhibitor phosphoramidon, at a concentration of 10(-6) mol/L, causes an inhibition in the response to big ET-1 by 52.6% in normal kidneys, whereas this inhibition with the same concentration of phosphoramidon was found to be significantly decreased in kidneys isolated from GLY-pretreated rabbits. 5. The non-selective NO synthase inhibitor N(G)-nitro-L- arginine methyl ester (L-NAME) caused a significant potentiation in the vasoconstrictor response to ET-1 in normal isolated perfused rabbit kidneys. However, L-NAME did not alter the responses to ET-1 in GLY-pretreated kidneys. 6. These results indicate that accumulation of reactive oxygen species causes an inhibition in NO bioavailability. Increased conversion of big ET-1 to ET-1 may also contribute to the mechanism of vascular damage due to GLY.


Endothelium, Vascular/drug effects , Glycerol/pharmacology , Kidney/blood supply , Kidney/drug effects , Nitric Oxide/metabolism , Animals , Arginine/physiology , Aspartic Acid Endopeptidases/metabolism , Dose-Response Relationship, Drug , Endothelin-1/administration & dosage , Endothelin-Converting Enzymes , Endothelium, Vascular/enzymology , Endothelium, Vascular/metabolism , Endothelium, Vascular/pathology , Female , Injections, Intra-Arterial , Kidney/enzymology , Kidney/pathology , Male , Metalloendopeptidases , Rabbits , Reactive Oxygen Species/metabolism , Renal Circulation/drug effects , Renal Circulation/physiology
...